Prediction Of Uncontrolled Dyslipidemia Of Cardiac Outpatients And The Adverse Effect Of Pharmaceutical Excipients
Uncontrolled dyslipidemia is still a difficult problem to be achieved during therapy of cardiac patients. Several authors stated contribution of patients’ adherence, physicians’ practice and active ingredients to attain goals of dyslipidemia control, but none combined all these causes. Unfortunat...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2013
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/43460/1/Hadeer%20Akram%20Abdulrazzaq24.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Uncontrolled dyslipidemia is still a difficult problem to be achieved during therapy
of cardiac patients. Several authors stated contribution of patients’ adherence,
physicians’ practice and active ingredients to attain goals of dyslipidemia control, but
none combined all these causes. Unfortunately few studies discussed the effects of
pharmaceutical excipients in clinical practice and especially dyslipidemia. Objectives
of this study were to determine predictors of uncontrolled dyslipidemia, poor lipid
profile, adverse drug reactions (ADRs), and effects of pharmaceutical excipients.
Second is implementation of an intervention tool to improve the knowledge of
healthcare professionals about pharmaceutical excipients. First objective was carried
out at Cardiac Clinic of Hospital Pulau Pinang in Malaysia, while the second was
conducted at Hospital Pulau Pinang (Malaysia) and Al-Kadhimiya Teaching Hospital
(Iraq). Dyslipidemia control and lipid profile were evaluated depending on the
National Cholesterol Education Program (NCEP) guideline. Validated questionnaires
were filled by patients to determine their adherence and common ADRs during
therapy. Healthcare professionals answered validated questionnaires; one for
physicians to determine their practice for dyslipidemia control, and another to assess
their knowledge about pharmaceutical excipients. Other information like patients’
characteristics, concurrent medications, diseases, and lipid profile were collected
from patients’ progress files. |
|---|